| COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know |
COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-14 17:01:16 |
Czytaj oryginał (ang.) |
| Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the web. |
businesswire.com |
2025-05-14 10:30:00 |
Czytaj oryginał (ang.) |
| COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript |
COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2025-05-08 15:14:09 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir. |
businesswire.com |
2025-05-08 10:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in. |
businesswire.com |
2025-04-29 10:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pat. |
businesswire.com |
2025-04-28 10:30:00 |
Czytaj oryginał (ang.) |
| Why Compass Pathways Stock Was a Double-Digit Winner This Week |
The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can be greeted with notable share price pops. |
fool.com |
2025-04-25 22:13:57 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on t. |
businesswire.com |
2025-04-22 10:00:00 |
Czytaj oryginał (ang.) |
| This Is a Test From GlobeNewswire |
This is a test from GlobeNewswire. Readers are advised to disregard. |
globenewswire.com |
2025-03-28 19:01:00 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depressant medications, if necessary, and those eligible will receive a dose of either 25 mg of COMP360 or placebo. “We are p. |
businesswire.com |
2025-03-26 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg. |
businesswire.com |
2025-03-18 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Participate in Stifel Virtual CNS Forum |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each. |
businesswire.com |
2025-03-11 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways: Betting On The Future Of Psilocybin Therapy |
Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before needing additional capital. COMP360 shows promise in treating treatment-resistant depression and PTSD, with significant clinical trial results and potential long-term economic benefits. |
seekingalpha.com |
2025-02-28 19:08:23 |
Czytaj oryginał (ang.) |
| COMPASS Pathways plc (CMPS) Q4 2024 Earnings Call Transcript |
COMPASS Pathways plc (NASDAQ:CMPS ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Lori Englebert - Chief Commercial Officer Teri Loxam - Chief Financial Officer Michael Gold - Chief Research & Development Officer Guy Goodwin - Chief Medical Officer Steve Levine - Chief Patient Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Paul Matteis - Stifel Ritu Baral - TD Cowen Charles Duncan - Cantor Leonid Timashev - RBC Capital Markets Patrick Trucchio - H.C. Wainwright & Co. François Brisebois – Oppenheimer Sumant Kulkarni - Canaccord Genuity Michael Rabinowitz - Maxim Group Vikram Purohit - Morgan Stanley Operator Ladies and gentleman thank you for standing by, and welcome to the COMPASS Pathways' Ltd. |
seekingalpha.com |
2025-02-27 12:41:48 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and full year 2024 and provided an update on recent progress across its business. “We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with top-line 6-week data expected. |
businesswire.com |
2025-02-27 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45th Annual Health Care Conference at 1:10 pm ET on March 3rd, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 da. |
businesswire.com |
2025-02-25 18:00:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025 |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in a. |
businesswire.com |
2025-02-18 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference at 8:40 am ET on February 12th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be. |
businesswire.com |
2025-02-05 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by. |
businesswire.com |
2025-01-21 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces Pricing of Underwritten Offering |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one. |
businesswire.com |
2025-01-10 09:01:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) |
LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either bi. |
businesswire.com |
2024-12-18 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Participate in December Investor Conferences |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings: 7th Annual Evercore ISI HealthCONx Conference: Fireside chat at 10:25am ET on December 3, 2024 Piper Sandler 36th Annual Healthcare Conference: Fireside ch. |
businesswire.com |
2024-11-25 18:00:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to participate in Stifel 2024 Healthcare Conference |
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. |
globenewswire.com |
2024-11-14 09:44:00 |
Czytaj oryginał (ang.) |
| Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity |
Compass Pathways plc obtained positive results from phase 2b study using COMP360 for treatment resistant depression patients; Primary endpoint met with statistically significant p-value of p |
seekingalpha.com |
2024-11-01 19:10:56 |
Czytaj oryginał (ang.) |
| COMPASS Pathways plc (CMPS) Q3 2024 Earnings Call Transcript |
COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Lori Englebert - Chief Commercial Officer Teri Loxam - Chief Financial Officer Michael Gold - Chief Research & Development Officer Guy Goodwin - Chief Medical Officer Conference Call Participants Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor François Brisebois - Oppenheimer Elemer Piros - Rodman Patrick Trucchio - H.C. Wainwright & Co. Tom Shrader - BTIG Sumant Kulkarni - Canaccord Genuity Operator Thank you for standing by. |
seekingalpha.com |
2024-10-31 16:49:05 |
Czytaj oryginał (ang.) |
| Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates |
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress. “Ensuring the success of our lead COMP360 program is our absolute priority. We remain confident that COMP360 can be an effective therapy for patients with serious mental illness and our focus on deliveri. |
businesswire.com |
2024-10-31 08:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024 |
LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024. The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in adva. |
businesswire.com |
2024-10-24 10:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to participate in three investor conferences in September |
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences: |
globenewswire.com |
2024-08-28 10:00:00 |
Czytaj oryginał (ang.) |
| Psychedelic Stocks: Focus On Their Cash |
Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. |
seekingalpha.com |
2024-08-15 16:30:00 |
Czytaj oryginał (ang.) |
| Psychedelic drug contender stocks drop after FDA rejects MDMA treatment |
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder. |
marketwatch.com |
2024-08-12 16:12:00 |
Czytaj oryginał (ang.) |
| COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript |
COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants Ritu Baral - TD Cowen Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Vikram Purohit - Morgan Stanley Gavin Clark-Gartner - Evercore ISI Sumant Kulkarni - Canaccord Genuity Tom Shrader - BTIG Elemer Piros - Rodman Operator Good day, ladies and gentlemen, and welcome to COMPASS Pathways' Second Quarter 2024 Conference Call. [Operator Instructions] As a reminder, this call is being recorded. |
seekingalpha.com |
2024-08-04 05:22:07 |
Czytaj oryginał (ang.) |
| Compass Pathways announces second quarter 2024 financial results and business highlights |
LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2024 and an update on recent business progress. |
globenewswire.com |
2024-08-01 10:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to announce second quarter financial results on August 1, 2024 |
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, and provide an update on recent business developments, on August 1, 2024. |
globenewswire.com |
2024-07-24 11:01:00 |
Czytaj oryginał (ang.) |
| Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies |
COMPASS Pathways' lead drug, COMP360, is a synthetic psilocybin in Phase 3 trials for TRD and Phase 2 for PTSD and AN. The company addresses unmet mental health needs through psychedelic therapies. COMP360 showed promising results in Phase 2 trials for PTSD, with significant improvements in depression symptoms. |
seekingalpha.com |
2024-07-08 14:11:19 |
Czytaj oryginał (ang.) |
| 3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers |
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy). |
investorplace.com |
2024-07-08 11:45:54 |
Czytaj oryginał (ang.) |
| 3 Psychedelic Stocks to Buy on the Dip: Summer 2024 |
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored. |
investorplace.com |
2024-07-02 19:43:02 |
Czytaj oryginał (ang.) |
| Compass Pathways appoints Lori Englebert as Chief Commercial Officer |
LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. |
globenewswire.com |
2024-06-26 10:30:00 |
Czytaj oryginał (ang.) |
| Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference |
LONDON, June 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference at 7:00 am ET on June 27, 2024. The company will also participate in a panel discussion titled “Commercialization of Novel Compounds in Psychiatry” at 12:00pm ET on June 27, 2024. |
globenewswire.com |
2024-06-24 20:01:00 |
Czytaj oryginał (ang.) |
| Should You Buy the Dip on Compass Pathways Stock? |
Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. |
fool.com |
2024-06-12 10:25:00 |
Czytaj oryginał (ang.) |
| Psychedelics Closer To Commercialization; Compass Far And Away The Leader |
Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through private placements. |
seekingalpha.com |
2024-05-23 16:15:00 |
Czytaj oryginał (ang.) |